JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

FDA Denies Approval of MDMA-Assisted Therapy for PTSD.

Karen Roush

The American journal of nursing November 1, 2024 DOI: 10.1097/01.naj.0001081684.80872.ce (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Psychedelic-assisted therapy MDMA PTSD
Keywords	PTSD Treatment Clinical trials Drug regulation Mental health
Key points	The FDA refused approval for MDMA-assisted therapy for PTSD, pointing to potential dangers and research flaws.

Abstract

The agency cited potential dangers and flaws in research methodology.

Reaction mixed over FDA committee rejection of MDMA therapy for PTSD Mental Health Weekly June 14, 2024
Much anticipated FDA decision about psychedelics for PTSD ends with denial Mental Health Weekly August 19, 2024
FDA publicly releases MDMA rejection letter; MAPS vows to press forward Mental Health Weekly September 15, 2025
FDA advisory committee rejects MDMA application for PTSD, but… Alcoholism & Drug Abuse Weekly June 10, 2024
MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward. CNS Drugs April 1, 2025 6 citations

Explore topics

Psychedelic-assisted therapy MDMA PTSD

By condition and practice

MDMA and psychedelic-assisted therapy MDMA for PTSD